SCM
MYGN icon

Sterling Capital Management’s Myriad Genetics MYGN Stock Holding History

Sterling Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6K Sell
1,864
-1,233
-40% -$5.6K ﹤0.01% 2189
2026
Q1 		$13.9K Sell
3,097
-2,151
-41% -$11.2K ﹤0.01% 2199
2025
Q4 		$32.3K Sell
5,248
-1,034
-16% -$7.5K ﹤0.01% 1983
2025
Q3 		$45.4K Buy
6,282
+3,886
+162% +$23.1K ﹤0.01% 1786
2025
Q2 		$12.7K Buy
2,396
+853
+55% +$5.04K ﹤0.01% 1983
2025
Q1 		$13.7K Sell
1,543
-1,321
-46% -$15.9K ﹤0.01% 1772
2024
Q4 		$39.3K Buy
2,864
+2,556
+830% +$47.2K ﹤0.01% 1682
2024
Q3 		$8.44K Buy
+308
New +$8.34K ﹤0.01% 1602
2017
Q4 		– Sell
-7,249
Closed -$262K – 926
2017
Q3 		$262K Sell
7,249
-1,841,523
-100% -$52.5M ﹤0.01% 844
2017
Q2 		$47.8M Sell
1,848,772
-32,878
-2% -$698K 0.46% 81
2017
Q1 		$36.1M Sell
1,881,650
-3,473
-0.2% -$61.5K 0.34% 95
2016
Q4 		$31.4M Sell
1,885,123
-206,014
-10% -$3.73M 0.28% 101
2016
Q3 		$43M Buy
2,091,137
+567,379
+37% +$14.4M 0.4% 86
2016
Q2 		$46.6M Buy
1,523,758
+90,420
+6% +$3.14M 0.43% 84
2016
Q1 		$53.6M Sell
1,433,338
-108,977
-7% -$4.11M 0.49% 76
2015
Q4 		$66.6M Sell
1,542,315
-303,307
-16% -$12.8M 0.59% 58
2015
Q3 		$69.2M Sell
1,845,622
-110,644
-6% -$3.93M 0.62% 61
2015
Q2 		$66.5M Buy
1,956,266
+278,843
+17% +$9.48M 0.6% 69
2015
Q1 		$59.4M Sell
1,677,423
-115,198
-6% -$4.12M 0.53% 76
2014
Q4 		$61.1M Buy
1,792,621
+1,070,349
+148% +$38M 0.53% 74
2014
Q3 		$27.9M Sell
722,272
-1,086,238
-60% -$40.5M 0.34% 88
2014
Q2 		$70.4M Sell
1,808,510
-331,934
-16% -$12.4M 0.61% 71
2014
Q1 		$73.2M Sell
2,140,444
-482,288
-18% -$14.9M 0.62% 64
2013
Q4 		$55M Buy
2,622,732
+233,618
+10% +$5.91M 0.5% 84
2013
Q3 		$56.1M Buy
2,389,114
+276,755
+13% +$7.86M 0.66% 69
2013
Q2 		$56.8M Buy
+2,112,359
New +$61.2M 0.7% 65

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sterling Capital Management's MYGN Position: Q2 2026 in Review

Sterling Capital Management reduced its Myriad Genetics (MYGN) stake by 40% in Q2 2026, selling an estimated $5.6K and leaving 1,864 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2189.

Sterling Capital Management first reported a position in MYGN in Q2 2013 and has held it in 26 quarters since. The position peaked at $73.2M in Q1 2014. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Sterling Capital Management held 1,864 shares of Myriad Genetics worth $10.6K as of Q2 2026.
  • Sterling Capital Management sold 1,233 Myriad Genetics shares in Q2 2026, an estimated $5.6K.
  • Myriad Genetics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2189 holding.
  • Sterling Capital Management first reported a position in Myriad Genetics in Q2 2013 and has held it in 26 quarters since.
  • Sterling Capital Management's Myriad Genetics position peaked at $73.2M in Q1 2014.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.